Indian Journal of Cancer
Home  ICS  Feedback Subscribe Top cited articles Login 
Users Online :331
Small font sizeDefault font sizeIncrease font size
Navigate Here
 »   Next article
 »   Previous article
 »   Table of Contents

Resource Links
 »   Similar in PUBMED
 »  Search Pubmed for
 »  Search in Google Scholar for
 »Related articles
 »   Citation Manager
 »   Access Statistics
 »   Reader Comments
 »   Email Alert *
 »   Add to My List *
 * Requires registration (Free)
 

 Article Access Statistics
    Viewed8628    
    Printed235    
    Emailed4    
    PDF Downloaded16    
    Comments [Add]    
    Cited by others 22    

Recommend this journal

 

 REVIEW ARTICLE
Year : 2003  |  Volume : 40  |  Issue : 3  |  Page : 87-100

Positron emission tomography imaging in evaluation of cancer patients.


Division of Nuclear Medicine, Department of Radiology, Hospital of the University of Pennsylvania, 110 Donner Bldg., 3400 Spruce Street, Philadelphia, PA 19104, USA

Correspondence Address:
A Alavi
Division of Nuclear Medicine, Department of Radiology, Hospital of the University of Pennsylvania, 110 Donner Bldg., 3400 Spruce Street, Philadelphia, PA 19104
USA
Login to access the Email id

Source of Support: None, Conflict of Interest: None


PMID: 14716112

Rights and PermissionsRights and Permissions

Positron emission tomography (PET) is a diagnostic imaging technique that has progressed rapidly from being a research technique in laboratories to a routine clinical imaging modality. The most widely used radiotracer in PET is Fluorine18-fluorodeoxyglucose (F18-FDG), which is an analogue of glucose. The FDG uptake in cells is directly proportional to glucose metabolism of cells. Since glucose metabolism is increased many fold in malignant tumors PET has a high sensitivity and a high negative predictive value. PET with FDG is now the standard of care in initial staging, monitoring the response to the therapy, and management of lung cancer, colonic cancer, lymphoma, melanoma, esophageal cancer, head and neck cancer and breast cancer. Other indications of PET like bone tumor, ovarian cancer and cancer of unknown primary (CUP) has also been discussed in brief. The aim of this review article is to review the clinical applications of PET in various malignancies and only limited number of important studies will be discussed for this effort.






[FULL TEXT] [PDF Not available]*


        
Print this article     Email this article

  Site Map | What's new | Copyright and Disclaimer
  Online since 1st April '07
  © 2007 - Indian Journal of Cancer | Published by Wolters Kluwer - Medknow